Stocktoria

Alector, Inc. ALEC

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-02-07 · LEI

Alector, Inc. financials (annual)

Revenue
$27.7M $21.2M $21.1M $207.1M $133.6M $97.1M $100.6M $21.0M 20182019202020212022202320242025
Net income
-$52.2M -$105.4M -$190.2M -$36.3M -$133.3M -$130.4M -$119.0M -$142.9M 20182019202020212022202320242025
Free cash flow
$125.6M -$114.6M -$171.8M $295.3M -$24.4M -$186.5M -$231.2M -$184.1M 20182019202020212022202320242025

Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue$21.0M$100.6M$97.1M$133.6M$207.1M$21.1M$21.2M$27.7M
R&D expense$123.1M$185.9M$192.1M$210.4M$189.4M$156.9M$100.5M$73.0M
Operating income-$156.0M-$145.0M-$151.7M-$137.8M-$37.4M-$195.2M-$114.4M-$57.3M
Income tax$168,000$128,000$5.2M$3.3M$0$0$0
Net income-$142.9M-$119.0M-$130.4M-$133.3M-$36.3M-$190.2M-$105.4M-$52.2M
EPS (diluted)$-1.39$-1.23$-1.56$-1.62$-0.45$-2.45
Operating cash flow-$184.0M-$229.9M-$184.2M-$20.3M$298.6M-$166.7M-$99.3M$127.5M
Free cash flow-$184.1M-$231.2M-$186.5M-$24.4M$295.3M-$171.8M-$114.6M$125.6M
Cash & equivalents$65.8M$33.0M$74.6M$154.3M$329.2M$50.0M$89.6M$65.5M
Total assets$293.2M$468.3M$621.8M$787.6M$814.7M$488.3M$421.9M$308.4M
Total liabilities$262.6M$341.5M$487.7M$573.2M$513.9M$220.7M$227.2M$195.2M
Shareholders' equity$30.6M$126.8M$134.2M$214.4M$300.7M$267.5M$194.7M-$97.4M

Growth · year-over-year · Revenue CAGR -3.8%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue growth-79.1%+3.6%-27.3%-35.5%+881.5%-0.6%-23.3%
Free cash flow growth-108.3%-191.2%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.